AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 MAR 4 - (NewsRx.com & NewsRx.net) -- Solvay Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved EstroGel (estradiol gel), the first-ever estrogen therapy (ET) transdermal gel in the country for the treatment of moderate to severe vasomotor symptoms, as well as vulvar and vaginal atrophy associated with menopause.
EstroGel is a clear, odorless, hydro-alcoholic gel that provides for delivery of estradiol for estrogen replacement in a non-patch transdermal form.
"With the approval of EstroGel, women and healthcare professionals now have an additional hormone therapy option. EstroGel will offer healthcare providers the opportunity to individualize a woman's therapy to help manage vasomotor symptom relief," said Harold H. Shlevin, PhD, president and CEO of Solvay Pharmaceuticals, Inc.
EstroGel has been a prescribed therapy for more than 25 years in Europe. It will be available with a prescription in pharmacies throughout the United States by mid-2004.
Transdermal delivery of EstroGel ensures the body receives a consistent and ...
Source: HighBeam Research, FDA approves first transdermal gel for estrogen therapy.